Fol. Biol. 2005, 51, 12-18
https://doi.org/10.14712/fb2005051010012
Characteristic of Two Mouse bcr-abl-Transformed Cell Lines: I. General Properties of the Cells
References
1. , I., Garcia-Lora, A., Cabrera, T., Ruiz-Cabello, F., Garrido, F. (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53, 904-910.
<https://doi.org/10.1007/s00262-004-0517-9>
2. , M., Korontsvit, T., Xu, Q., Mackinnon, S., Yang, S. Y., Sette, A., Scheinberg, D. A. (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87, 3587-3592.
<https://doi.org/10.1182/blood.V87.9.3587.bloodjournal8793587>
3. , J., Vonka, V. (2003) MHC class I status of tumours and design of immunotherapeutic strategies. Immunol. Lett. 90, 177-178.
4. , K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., Scheinberg, D. A. (2004) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037-1042.
<https://doi.org/10.1182/blood-2003-03-0954>
5. , G. Q., Baltimore, D. (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316.
<https://doi.org/10.1073/pnas.85.23.9312>
6. , M., Daley, G. (2001) Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood 97, 3491-3497.
<https://doi.org/10.1182/blood.V97.11.3491>
7. , M. W., Zeng, Y ., Feng, H., Katsanis, E. (2003) Tumor derived chaperone-rich cell lysates are effective therapeutic vaccines against variety of cancers. Cancer Immunol. Immunother. 52, 226-234.
<https://doi.org/10.1007/s00262-002-0359-2>
8. , L., Feng, H., Raymond, A., Kreeger, M., Zeng, Y ., Graner, M., Whitesell, L., Katsanis, E. (2001) Dendritic-cellpeptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother. 50, 31-40.
<https://doi.org/10.1007/PL00006680>
9. , D. T. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br. J. Haematol. 113, 11-23.
<https://doi.org/10.1046/j.1365-2141.2001.02558.x>
10. , J. B., Witte, O. N. (1985) Activation of the abl oncogene in murine and human leukemias. Biochim. Biophys. Acta 823, 1-17.
11. , O. C., Kessler, J. H., Huijbers, I. J., Ten Bosch, G. J., Melief, C. J. (2000) BCR-ABL directed immunotherapy: a virtual reality? Leuk. Lymphoma 38, 175-181.
<https://doi.org/10.3109/10428190009060331>
12. , J., Chianese, E., Witte, O. N. (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84, 6558-6562.
<https://doi.org/10.1073/pnas.84.18.6558>
13. , J. V., Deininger, M. W. (2004) Biology of chronic myelogenous leukaemia – signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North. Am. 18, 545-568.
<https://doi.org/10.1016/j.hoc.2004.03.008>
14. , L. C., Clark, R. E., Christmas, S. E. (2000) b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br. J. Haematol. 109, 616-621.
<https://doi.org/10.1046/j.1365-2141.2000.02090.x>
15. , R. L. (1998) Method used to study structure and function of the nucleolus. Methods Cell Biol. 53, 303-321.
<https://doi.org/10.1016/S0091-679X(08)60884-5>
16. , Y., Takahashi, M., Zheng, Z., Koike, T., Toba, K., Liu, A., Furukawa, T., Aoki, S., Aizawa, Y. (1999) Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13, 166-174.
<https://doi.org/10.1038/sj.leu.2401311>
17. , R., Steinmetz, M. (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727-734.
<https://doi.org/10.1016/S0092-8674(85)80053-2>
18. , J., Cathcart, K., Korontsvit, T., Soignet, S., Bocchia, M., Caggiano, J., Lai, L., Jimenez, J., Kolitz, J., Scheinberg, D. A. (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95, 1781-1787.
<https://doi.org/10.1182/blood.V95.5.1781.005k46_1781_1787>
19. , K. (1980) Nucleoli in maturing blood cells. Topic. Rev. Haematol. 1, 115-137.
20. , K., Lejnar, J., Potměšil, M. (1967) A note to the demonstration of DNA in nuclei of blood cells in smear preparations. Folia Haematol. 88, 305-317.
21. , K., Jirásková, I., Perlaky, L., Busch, H. (1999) The silver reaction of nucleolar proteins in the main structural compartments of ring shaped nucleoli in smear preparation. Acta Histochem. 101, 167-183.
<https://doi.org/10.1016/S0065-1281(99)80016-6>
22. , K. (2002) Structural features of nucleoli in blood, leukemic, lymphoma and myeloma cells. Eur. J. Histochem. 46, 125-132.
<https://doi.org/10.4081/1661>
23. , K. (2003) To the nucleolar structure and cytochemistry (Nucleoli as useful markers of various cell states). Recent Res. Develop. Life Sci. 1, 253-263.
24. , G. J., Toornvliet, A. C., Friede, T., Melief, C. J., Leeksma, O. C. (1995) Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9, 1344-1348.
25. , P., Firat, H., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J. P., Lemonnier, F. A., Leblond, V., LangladeDemoyen, P. (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101, 2290-2296.
<https://doi.org/10.1172/JCI488>
26. , Y., Graner, M. W., Feng, H., Li, G., Katsanis, E. (2004) Imatinib mesylate efectively combines with chaperonerich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukaemia. Int. J. Cancer 110, 251-259.
<https://doi.org/10.1002/ijc.20115>
